Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06834646

Comparison of 30-day Morbidity and Mortality in Cancer Patients Based on Emergency Department Location

Patients being followed for cancer account for 2.8% of emergency admissions in France. An acute episode that triggers a visit to the emergency department may be related to the progression of the disease, or to complications of treatment. The management of these patients is often complex and requires a degree of expertise. Emergency departments specialising in the management of cancer complications have been set up, and now deal exclusively with patients treated at their centres. However, for geographical or logistical reasons, patients with cancer are likely to consult a non-specialist emergency department and/or one located outside the cancer care centre. In this case, the emergency doctor may not have access to the oncology file, and care in the emergency department and downstream services may be sub-optimal. Studies have shown a positive impact on the quality of care and prognosis of patients thanks to the cancer centre's expertise. However, the effect of the centre on a cancer patient who visits the emergency department has never been studied. This is particularly true if the emergency department where the patient is seen is located in the cancer follow-up centre.

The primary objective of the COVER study is to investigate the impact of the location of the emergency department where the patient is seen for their prognosis.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hôpital Pitié Salpêtrière Emergency department

Paris, 75013, France

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients aged 18 or over admitted to an emergency department with cancer that has been active or in remission for less than a year.

Exclusion criteria

  • Opposition to participate in the study

Treatment and study plan

Primary outcomes

  1. Number of days alive spent outside the hospital

    Time frame: 1 month

Secondary outcomes

  1. Occurrence of a new/ unscheduled consultation

    Time frame: 30 days

  2. Length of hospitalisation

    Time frame: 90 day

  3. Unscheduled consultation or hospitalization emergency department discharge

    Time frame: 7 days

  4. Unexpected death

    Time frame: 7 days

  5. Secondary admission to the intensive care unit during the initial hospitalization following the emergency visit

    Time frame: 7 days

  6. Occurence of organ failure

    Time frame: 7 days

  7. Quality of life with QLQ-C30

    Time frame: 90 days

    QLQ-C30

  8. Mortality

    Time frame: 30 days

  9. Mortality

    Time frame: Day 90

Study contacts

Contact information is provided by the study sponsor or research team.

Olivier PEYRONY, MD, PhD

CONTACT

[email protected]

00 33 (0) 142494939

Yonathan FREUND, PU-PH

CONTACT

[email protected]

00 33 (0) 184827129

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

Comparison of 30-day Morbidity and Mortality in Cancer Patients Based on Emergency Department Location: Referring Oncology Hospital vs Other Hospitals.

Acronym: COVER

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Feb 19, 2025
Registry last updated
Jan 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.